Eric M. Horwitz, MD, FABS, FASTRO
- Request Appointment
- Clinical Locations
- About
- Education and Training
- Patient Stories
- Research Profile
- Publications
- Ratings
Clinical Locations
Primary Location
Fox Chase Cancer Center
333 Cottman Avenue
Philadelphia, PA 19111
Chair, Radiation Oncology
Professor
Gerald E. Hanks Endowed Chair in Radiation Oncology
Kidney, Bladder, and Prostate Cancer TRDG Member
NCCN, Prostate Cancer Panel Member
Specialties
Treatment Focus
- Intensity Modulated Radiation Therapy (IMRT)
- Stereotactic body Radiation Therapy (SBRT)
- HDR temporary prostate brachytherapy
- LDR permanent prostate brachytherapy
Key Awards
Radiation Oncology
Treatment Philosophy
In addition to my focus on treating and caring for patients with prostate and bladder cancer, it is my responsibility as Chairman of the Department of Radiation Oncology at Fox Chase; an NCI designated National Comprehensive Cancer Center to promote the mission of the Center to prevail over cancer. Our department's expertise has always focused on developing and integrating sophisticated technology into successful treatment for our cancer patients and I remain committed to continuing and expanding this legacy. However, the successful treatment of a patient is not just based on the technology that is available. Being diagnosed with cancer and receiving treatment is one of the most difficult things that many people will ever face, and it is crucial that we as caregivers do not forget this. Caring for patients as one important part of a multidisciplinary team allows us in the Department of Radiation Oncology to provide the best possible care for our patients.
Educational Background
- Resident, Radiation Oncology, William Beaumont Hospital, Royal Oak, MI
- MD, Albany Medical College, Albany, NY, 1992
- BA, History, Chemistry minor, University of Pennsylvania, Philadelphia, PA, 1988
Certifications
- American Board of Radiology, Radiation Oncology
Memberships
- National Comprehensive Cancer Network (NCCN)
- Prostate Cancer Panel
- American Society of Radiation Oncology (ASTRO)
- American Brachytherapy Society (ABS)
- American Board of Radiology (ABR)
- American Medical Association (AMA)
Honors & Awards
- Philadelphia Magazine Top Doctors, 2002, 2005-19
- Inaugural Fellow, American Brachytherapy Society (ABS), 2017
- America’s Top Doctors®, 2015-17
- Newsweek Top Cancer Doctors, 2015
- Best Doctors in America®, 2013-14
- Volunteer Service Award, American Board of Radiology, 2014
- Distinguished Service Award, American Brachytherapy Society, 2010
Daniel Haubrich
Daniel Haubrich
After Daniel Haubrich was diagnosed with prostate cancer in 2005, his urologist did not think he was a good candidate for surgery, and he offered Daniel little hope that he would make a full recovery. Daniel knew he needed a second opinion and scheduled an appointment at Fox Chase Cancer Center to see a more experienced surgeon. This time, he was recommended for surgery, and after both surgery and radiation in early 2006, he is now cancer free. "I am grateful to both Dr. Chen and Dr. Horwitz for their positive attitudes, their commitment to care, and for treating me with respect," he said. "My experience at Fox Chase was always positive."
Kevin Logan
Kevin Logan
In 2010, Kevin Logan noticed a lump on his neck which turned out to be squamous cell carcinoma on the base of his tongue. Upon the recommendation to seek treatment at Fox Chase Cancer, that's where Kevin and his wife, Devra, went even though it was a three-hour drive from their home in Maryland. Kevin underwent a successful treatment of surgery, chemotherapy, and radiation, and once he finished treatment, he returned to work full-time. "Many people who knew about my cancer often called to ask where I was treated, and I’m always telling them, 'Fox Chase is the place to go,' and I always will," he said.
Ed Horowitz
Ed Horowitz
When Ed Horowitz was diagnosed with prostate cancer in 2008, he had to make a decision whether to undergo radiation or surgery. After receiving one opinion from a surgeon at a large Philadelphia hospital, he decided to seek a second opinion from Dr. Eric Horwitz, chair of radiation oncology at Fox Chase Cancer Center. Ed liked Dr. Horowitz's warm demeanor and sense of humor and decided to be treated with IMRT (intensity modulated radiation therapy) combined with hormone injections, followed by radiation and hormone therapy. The treatment was successful. A few years later, his cancer returned, isolated to his shoulder this time. Ed started another course of chemotherapy in March 2016. "My cancer has not grown and has not spread since I completed chemotherapy," he said. "I always recommend Fox Chase to anyone considering treatment for prostate cancer. I consider myself fortunate to have gone there for treatment."
James Slade
James Slade
I was in my early 60s when my first PSA blood test detected slightly elevated levels, and I was advised to be retested 8 months later. When the levels increased 50% on the second test, my doctor in New Jersey performed a biopsy. The diagnosis was prostate cancer.
John Donahue
John Donahue
John Donahue was concerned about prostate cancer. From the time he had surgery for an enlarged prostate, John was always aware of his PSA (prostate-specific antigen) level (a protein produced by the cells of the prostate gland). Although his levels were within normal range, they were on an upward climb over a period of 3 to 4 years.
Pages
Research Interests
- Determining outcomes in treatment for prostate cancer patients treated with external beam radiation and brachytherapy
- Developing image guidance techniques for prostate cancer radiation
- Developing new bladder preservation techniques to treat patients with muscle invasive bladder cancer
Selected Publications
Rosenthal SA, Hu C, Sartor O, Gomella LG, Amin MB, Purdy J, Michalski JM, Garzotto MG, Pervez N, Balogh AG, Rodrigues GB, Souhami L, Reaume MN, Williams SG, Hannan R, Horwitz EM, Raben A, Peters CA, Feng FY, Shipley WU, Sandler HM. Effect of Chemotherapy With Docetaxel With Androgen Suppression and Radiotherapy for Localized High-Risk Prostate Cancer: The Randomized Phase III NRG Oncology RTOG 0521 Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology:Jco1802158, 2019. PubMed
Martin, J.M., Li, T., Johnson, M.E., Murphy, C.T., Howald, A.G., Smaldone, M.C., Kutikov, A., Chen, D.Y., Viterbo, R., Greenberg, R.E., Uzzo, R.G., Horwitz, E.M. Use of Postprostatectomy Radiation Therapy at an NCI-Designated Comprehensive Cancer Center. J Natl Compr Canc Netw 13: 525-30; 2015. PubMed
Horwitz, E.M. and Weinberg, D.S. Medicare physician payment data: Is this transparency? Ann. Int. Med. 161(4): 291-292; 2014. PubMed
Horwitz EM. ABS brachytherapy consensus guidelines. Brachytherapy. 11(1): 4-5, 2012. PubMed
Davis BJ, Horwitz EM, Lee WR, Crook, J. M.; Stock, R. G.; Merrick, G. S.; Butler, W. M.; Grimm, P. D.; Stone, N. N.; Potters, L.; Zietman, A. L.; Zelefsky, M. J. American Brachytherapy Society consensus guidelines for transrectal ultrasound-guided permanent prostate brachytherapy. Brachytherapy 11(1):6-19, 2012. PubMed
Crook, J.M.; O'Callaghan, C.J.; Duncan, G.; Dearnaley, D.P.; Higano, C.S.; Horwitz, E.M.; Frymire, E.; Malone, S.; Chin, J.; Nabid, A.; Warde, P.; Corbett, T.; Angyalfi, S.; Goldenberg, S.L.; Gospodarowicz, M.K.; Saad, F.; Logue, J.P.; Hall, E.; Schellhammer, P.F.; Ding, K.; Klotz, L. Intermittent androgen suppression for rising PSA level after radiotherapy. New England Journal of Medicine 367: 895-903; 2012. PubMed
Rosenthal, S.A.; Bittner, N.H.; Beyer, D.C.; Demanes, D.J.; Goldsmith, B.J.; Horwitz, E.M.; Ibbott, G.S.; Lee, W.R.; Nag, S.; Suh, W.W.; Potters, L. American Society for Radiation Oncology (ASTRO) and American College of Radiology (ACR) practice guideline for the transperineal permanent brachytherapy of prostate cancer. International Journal of Radiation Oncology Biology Physics 79: 335-41; 2011. PubMed
Horwitz, E.M. Why External Beam Radiotherapy Is Treatment of Choice for Most Men With Early-stage Nonmetastatic Prostate Cancer. Urology 73: 470-472; 2009. PubMed
Horwitz, E.M.; Bae, K.; Hanks, G.E.; Porter, A.; Grignon, D.; Brereton, H.; Venkatesan, V.; Lawton, C.A.; Rosenthal, S.A.; Sandler, H.M.; Shipley, W.U. Ten-Year Follow-Up of RTOG 92-02: A Phase III Trial of the Duration of Elective Androgen Deprivation in Locally Advanced Prostate Cancer. Journal of Clinical Oncology 26: 2497-2504; 2008. PubMed
Langer, C.J.; Harris, J.; Horwitz, E.M.; Nicolaou, N.; Kies, M.; Curran, W.J.; Wong, S.J.; Ang, K.K. Phase II study of paclitaxel, cisplatin in combination with split course concomitant hyperfractionated re-irradiation in patients with recurrent squamous cell cancer of the head and neck cancer: Preliminary results of RTOG 99-11. Journal of Clinical Oncology 25: 4800-4805; 2007. PubMed
Horwitz, E.M.; Levy, L.B.; Thames, H.D.; Kuban, D.A.; Kupelian, P.A.; Martinez, A.A.; Michalski, J.M.; Pisansky T.M.; Sandler, H.M.; Shipley, W.U.; Zelefsky, M.J.; Hanks, G.E.; Zietman, A.L. The Biochemical And Clinical Significance Of The Post-Treatment PSA Bounce For Prostate Cancer Patients Treated With External Beam Radiation Therapy Alone: A Multi-Institutional Pooled Analysis. Cancer 1071: 1496-1502; 2006. PubMed
Kuban, D.A.; Levy, L.B.; Potters, L.; Beyer, D.C.; Blasko, J.C.; Moran, B.J.; Ciezki, J.P.; Zietman, A.L.; Zelefsky, M.J.; Pisansky, T.M.; Elshaikh, M.; Horwitz, E.M. Comparison of biochemical failure definitions for permanent prostate brachytherapy. International Journal of Radiation Oncology Biology and Physics 65: 1487-1493; 2006. PubMed
Horwitz, E.M.; Thames, H.D.; Kuban, D.A.; Levy, L.B.; Kupelian, P.A.; Martinez, A.A.; Michalski, J.M.; Pisansky T.M.; Sandler, H.M.; Shipley, W.U.; Zelefsky, M.J.; Hanks, G.E.; Zietman, A.L. Definitions Of Biochemical Failure That Best Predict Clinical Failure In Prostate Cancer Patients Treated With External Beam Radiation Alone - A Multi-Institutional Pooled Analysis. Journal of Urology 173:797-802; 2005. PubMed
Horwitz, E.M.; Uzzo, R.G.; Hanlon, A.L.; Greenberg, R.E.; Hanks, G.E.; Pollack, A. Modifying the ASTRO definition of biochemical failure to minimize the influence of backdating in patients with prostate cancer treated with 3D conformal radiation therapy alone. Journal of Urology 169: 2153-2159; 2003. PubMed
Hanks, G.E.; Hanlon, A.L.; Epstein, B.; Horwitz, E.M. Dose response in prostate cancer with 8-12 year follow-up. International Journal of Radiation Oncology Biology and Physics 54: 427-435; 2002. PubMed
Additional Publications
Related Articles
14 PATIENT COMMENTS
-
5.0
February 17, 2019
Considering Dr. Horwitz' responsibilities & busy schedule, I always feel like I am the ONLY ONE on his sched.
-
5.0
February 12, 2019
Dr. Eric Horwitz, anesthesiologists, nurses and staff were very attentive and informative.
-
5.0
February 07, 2019
Excellent care [...].
-
5.0
January 03, 2019
Dr. Horwitz was amazing both knowledgeable & personable!
-
5.0
November 27, 2018
No problems.
-
5.0
October 25, 2018
I saw provider, resident & intern all were EXCELLENT!
-
5.0
September 04, 2018
Excellent bedside manner.
-
5.0
August 29, 2018
The best at what he does. Excellent bedside manner!
-
5.0
August 13, 2018
One of the best doctors that I have experienced in my life.
-
5.0
August 07, 2018
Very good!
-
5.0
August 02, 2018
ALL VERY GOOD.
-
No Star Ratings Available
July 27, 2018
i'm very satisfied with my doctor [...]
-
5.0
July 12, 2018
All my experiences were positive.
-
5.0
June 19, 2018
Dr. Horwitz has extended my life expectancy.
LOAD MORE